Cancer Chemotherapy and Pharmacology

, Volume 32, Issue 3, pp 215–220 | Cite as

Phase I trial of a 5-day infusion ofL-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies

  • Frank H. Valone
  • David R. Gandara
  • Judith A. Luce
  • Susan Wall
  • Edith A. Perez
  • Natalie Braham
  • Martine George
  • Laurie Letvak
Original Articles L-Leucovorin, 5-Fluorouracil, Advanced Gastrointestinal Malignancies


The combination of leucovorin [(6d,l)-5-formyltetrahydrofolate] and 5-fluorouracil (5-FU) has increased efficacy compared to 5-FU alone as treatment of advanced colorectal cancer. Leucovorin is metabolized to methylene tetrahydrofolate, which potentiates the antitumor actions of 5-FU by forming a ternary complex of thymidylate synthase, fluorodeoxyuridine and methylene tetrahydrofolate. Onlyl-leucovorin is metabolized to methylene tetrahydrofolate and forms this ternary complex. However,d-leucovorin may not be inert.d-Leucovorin may impair cellular uptake and metabolism ofl-leucovorin, thereby inhibiting the actions ofl-leucovorin. Because of this possible limitation to the effectiveness of racemic leucovorin, we have begun to explore the effects of the pure, biologically active isomer,l-leucovorin. In this phase I trial, patients with advanced gastrointestinal malignancies were treated with a 5-day continuous infusion ofl-leucovorin and daily intravenous boluses of 5-FU at 370 mg/m2. The dose ofl-leucovorin was escalated in groups of three patients at four doses, 200 mg/m2 per day, 400 mg/m2 per day, 700 mg/m2 per day and 1000 mg/m2 per day. Treatment was repeated every 28 days. Seventeen patients with advanced gastrointestinal cancers entered the trial. Sixteen patients were evaluable for toxicity. Toxicity was similar to that expected for leucovorin plus 5-FU. The most common severe toxicities (and the number of patients affected) were: diarrhea (2), mucositis (2), nausea/vomiting (1), and abdominal/rectal pain (2). The maximum tolerated dose ofl-leucovorin was 700 mg/m2 per day. Twelve patients were evaluable for response. One complete, one partial and one minor response were observed. All responses occurred among the nine patients with colorectal carcinomas. The combination ofl-leucovorin and 5-FU is well tolerated by patients and appears active for treatment of advanced colorectal carcinomas. Additional clinical trials are necessary to determine ifl-leucovorin is more effective thand,l-leucovorin for modulating the effectiveness of 5-FU.


Colorectal Carcinoma Ternary Complex Leucovorin Advanced Colorectal Cancer Methylene Tetrahydrofolate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ardalan B, Singh G, Silberman H (1988) A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J Clin Oncol 6: 1053–1058Google Scholar
  2. 2.
    Bertrand R, Jolivet J (1989) Lack of interference by the unnatural isomer of 5-formyltetrahydrofolate with the effects of the natural isomer in leucovorin preparations. J Natl Cancer Inst 81:1175–1178Google Scholar
  3. 3.
    Doroshow JH, Multhauf P, Leong L, et al (1990) Prospective randomized comparison of fluorouracil versus fluorouracil and highdose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 8:491–501Google Scholar
  4. 4.
    Doroshow JH, Newman E, Flanagan G, et al (1991) Phase I and clinical pharmacokinetic study of continuous infusion 6S-leucovorin (l-LV) and bolus 5-FU in patients with advanced cancer. Proc Am Soc Clin Oncol 10:97AGoogle Scholar
  5. 5.
    Erlichman C, Fine S, Wong A, et al (1988) A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 6:469–475Google Scholar
  6. 6.
    Hines JD, Zakem MH, Adelstein DJ, et al (1987) Biovailability of high-dose oral leucovorin. Natl Cancer Inst Monogr 5:57–60Google Scholar
  7. 7.
    Houghton JA, Williams LG, De Graaf SS, et al (1990) Relationship between dose rate of [6RS]leucovorin administration, plasma concentrations of reduced folates, and pools of 5,10-methylenetetrahydrofolates and tetrahydrofolates in human colon adenocarcinoma xenografts. Cancer Res 50:3493–3502Google Scholar
  8. 8.
    Keyomarsi K, Moran RG (1988) Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells. J Biol Chem 263:14402–14409Google Scholar
  9. 9.
    Lokich JJ, Ahlgren JD, Gullo JJ, et al (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 7:425–432Google Scholar
  10. 10.
    Machover D, Goldschmidt E, Chollet P, et al (1986) Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. J Clin Oncol 4:685–696Google Scholar
  11. 11.
    Machover D, Grison X, Goldschmidt E et al (1992) Fluorouracil combined with the pure (6S)stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma: a phase I–II study. J Natl Cancer Inst 84:321–327Google Scholar
  12. 12.
    McGuire BW, Sia LL, Haynes JD, et al (1987) Absorption kinetics of orally administered leucovorin calcium. Natl Cancer Inst Monogr 5: 47–56Google Scholar
  13. 13.
    Moertel CG (1978) Chemotherapy of gastrointestinal cancers. N Engl J Med 299:1049–1052Google Scholar
  14. 14.
    Moran RG, Scanlon KL (1991) Schedule-dependent enhancement of the cytotoxicity of fluoropyrimidines to human carcinoma cells in the presence of folinic acid. Cancer Res 51:4618–4623Google Scholar
  15. 15.
    Newman EM, Straw JA, Doroshow JH (1989) Pharmacokinetics of diastereoisomers of (6R,S)folinic acid (leucovorin) in humans during constant high-dose intravenous infusion. Cancer Res 49:5755–5760Google Scholar
  16. 16.
    Petrelli N, Douglass HO Jr, Herrera L, et al (1989) The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 7:1419–1426Google Scholar
  17. 17.
    Piedbois P, Buyse M, Rustum Y, et al (1992) Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin OncolGoogle Scholar
  18. 18.
    Poon MA, O'Connell MJ, Moertel CG, et al (1989) Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in advanced colorectal carcinoma. J Clin Oncol 7:1407–1418Google Scholar
  19. 19.
    Poon MA, O'Connell MJ, Wieand HS, et al (1991) Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9:1967–1972Google Scholar
  20. 20.
    Radparvar S, Houghton PJ, Houghton JA (1986) Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2′-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem Pharmacol 38: 335–342Google Scholar
  21. 21.
    Sato JK, Moran RG (1984) Interaction of methotrexate and citrovorum factor at folyl polyglutamate synthetase. Proc Am Assoc Cancer Res 25:312Google Scholar
  22. 22.
    Schilsky RL, Ratain MJ (1990) Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administrations. J Natl Cancer Inst 82:1411–1415Google Scholar
  23. 23.
    Sirotnak FM, Chello PL, Moccio DM, et al (1979) Stereospecificity at carbon 6 of formyltetrahydrofolate as a competitive inhibitor of transport and cytotoxicity of methotrexate in vitro. Biochem Pharmacol 28:2993–2997Google Scholar
  24. 24.
    Straw JA, Szapary D, Wynn WT (1984) Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. Cancer Res 44:3114–3119Google Scholar
  25. 25.
    Ullman G, Lee M, Martin DW, et al (1978) Cytotoxicity of 5-fluoro-2′-deoxyuridine: Requirement for reduced folate cofactors and antagonism by methotrexate. Proc Natl Acad Sci USA 75:980–983Google Scholar
  26. 26.
    Valone FH, Friedman MA, Wittlinger PS, et al (1989) Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin. A randomized trial of the Northern California Oncology Group. J Clin Oncol 7:1427–1436Google Scholar
  27. 27.
    Valone FH, Gandara DR, Deisseroth AB, et al (1991) Interleukin 2, cisplatin and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas. J Biol Response Mod 10:207–213Google Scholar
  28. 28.
    Wadler S, Schwartz EL (1990) Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 50:3473–3486Google Scholar
  29. 29.
    Wadler S, Schwartz EL, Goldman M, et al (1989) 5-Fluorouracil and recombinant alpha-2a-interferon: a active regimen against colorectal carcinoma. J Clin Oncol 7:1769–1775Google Scholar
  30. 30.
    White JC, Bailey BD, Goldman ID (1978) Lack of stereospecificity at carbon 6 of methyltetrahydrofolate transport in Ehrlich ascites tumor cells. Carrier-mediated transport of both stereoisomers. J Biol Chem 253:242–245Google Scholar
  31. 31.
    Wright JE, Dreyfuss A, el-Magharbel I, et al (1989) Selective expansion of 5,10-methylenetetrahydrofolate pools and modulation of 5-fluorouracil antitumor activity by leucovorin in vivo. Cancer Res 49:2592–2596Google Scholar
  32. 32.
    Zheng-Gang Z, Rustum YM (1991) Effects of diastereoisomers of 5-formyltetrahydrofolate on cellular growth, sensitivity to 5-fluoro-2′-deoxyuridine, and methylenetetrahydrofolate polyglutamate levels in HCT-8 cells. Cancer Res 51:3476–3481Google Scholar

Copyright information

© Springer-Verlag 1993

Authors and Affiliations

  • Frank H. Valone
    • 1
  • David R. Gandara
    • 2
  • Judith A. Luce
    • 3
  • Susan Wall
    • 4
  • Edith A. Perez
    • 2
  • Natalie Braham
    • 1
  • Martine George
  • Laurie Letvak
  1. 1.Department of MedicineVA Medical CenterSan FranciscoUSA
  2. 2.VA Medical CenterMartinezUSA
  3. 3.San Francisco General HorspitalSan FranciscoUSA
  4. 4.Department of RadiologyVA Medical CenterSan FranciscoUSA

Personalised recommendations